NASDAQ:IMGN - ImmunoGen Stock Price, Forecast & News

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

ImmunoGen, Inc. (NASDAQ:IMGN) announced its quarterly earnings data on Friday, November, 1st. The biotechnology company reported ($0.15) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.19) by $0.04. The biotechnology company had revenue of $13.30 million for the quarter, compared to the consensus estimate of $10.38 million. ImmunoGen had a negative return on equity of 573.09% and a negative net margin of 292.57%. ImmunoGen's quarterly revenue was up 22.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.32) EPS. View ImmunoGen's Earnings History.

ImmunoGen is scheduled to release their next quarterly earnings announcement on Friday, February 14th 2020. View Earnings Estimates for ImmunoGen.

9 Wall Street analysts have issued 1-year target prices for ImmunoGen's shares. Their forecasts range from $2.50 to $5.00. On average, they anticipate ImmunoGen's stock price to reach $3.28 in the next twelve months. This suggests that the stock has a possible downside of 8.4%. View Analyst Price Targets for ImmunoGen.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 1 sell rating, 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ImmunoGen.

News articles about IMGN stock have trended somewhat negative recently, according to InfoTrie. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. ImmunoGen earned a coverage optimism score of -1.6 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for ImmunoGen.

ImmunoGen saw a increase in short interest during the month of November. As of November 29th, there was short interest totalling 8,500,000 shares, an increase of 8.6% from the November 14th total of 7,830,000 shares. Based on an average daily volume of 1,848,700 shares, the days-to-cover ratio is currently 4.6 days. Approximately 5.8% of the shares of the stock are sold short. View ImmunoGen's Current Options Chain.

Some companies that are related to ImmunoGen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Immunomedics (IMMU), NVIDIA (NVDA), Micron Technology (MU), Seattle Genetics (SGEN), Synergy Pharmaceuticals (SGYP), Pfizer (PFE), Exelixis (EXEL), Nektar Therapeutics (NKTR), Alibaba Group (BABA) and Gilead Sciences (GILD).

ImmunoGen's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (9.76%), State Street Corp (4.15%), Squarepoint Ops LLC (0.40%), Alps Advisors Inc. (0.20%), Barclays PLC (0.17%) and Man Group plc (0.16%). Company insiders that own ImmunoGen stock include Anna Berkenblit, Daniel M Junius, David Brannon Johnston, Mark Alan Goldberg, Mark J Enyedy, Richard J Gregory and Thomas Ryll. View Institutional Ownership Trends for ImmunoGen.

IMGN stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Barclays PLC, Virtu Financial LLC, Alps Advisors Inc., Janney Montgomery Scott LLC and grace capital. Company insiders that have sold ImmunoGen company stock in the last year include Mark J Enyedy, Richard J Gregory and Thomas Ryll. View Insider Buying and Selling for ImmunoGen.

IMGN stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Redmile Group LLC, Squarepoint Ops LLC, SG Americas Securities LLC, Chicago Equity Partners LLC, Voloridge Investment Management LLC, Commonwealth Equity Services LLC and California Public Employees Retirement System. View Insider Buying and Selling for ImmunoGen.

Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IMGN stock can currently be purchased for approximately $3.58.

ImmunoGen has a market capitalization of $535.93 million and generates $53.82 million in revenue each year. The biotechnology company earns $-168,840,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. ImmunoGen employs 296 workers across the globe.View Additional Information About ImmunoGen.

The official website for ImmunoGen is http://www.immunogen.com/.

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected]